What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2024-05-09 compared with 2023-11-02 · 43 added, 3 removed, 22 unchanged (68% of the section changed)

Other Information

(c) During the last fiscal quarter, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement.

(c) During the last fiscal quarter, no director or officer (as defined in Exchange Act Rule 16a-1(f)) adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (within the meaning of SEC rules).

Exhibit Number

3 unchanged sentences

4.1 Specimen Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registrant’s Form 10-Q filed on August 5, 2022)

10.1 Amendment No.

2 to Credit Agreement, dated April 25, 2024, by and among QuidelOrtho Corporation, the lenders party thereto, and Bank of America, N.A., as Administrative Agent (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on April 29, 2024)

10.2(1) Employment Offer Letter, dated April 30, 2024, between QuidelOrtho Corporation and Brian J.

Blaser (incorporated by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed on May 7, 2024)

31.1* Certification by Principal Executive Officer of QuidelOrtho Corporation pursuant to Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

8 unchanged sentences

** Furnished herewith.

(1) Indicates a management plan or compensatory plan or arrangement.

SUMMARY OF ABBREVIATED TERMS

QuidelOrtho Corporation and its consolidated subsidiaries may be referred to as QuidelOrtho, the Company, we, our or us in this Quarterly Report, unless the context otherwise indicates.

Throughout this Quarterly Report, we have used terms which are defined below:

Annual Report Annual Report on Form 10-K for the fiscal year ended December 31, 2023

AOCI Accumulated other comprehensive loss

CEO Chief Executive Officer

CFO Chief Financial Officer

CODM Chief Operating Decision Maker

Combinations Business combination consummated by Quidel and Ortho on May 27, 2022, pursuant to a Business Combination Agreement entered into as of December 22, 2021, by and among Quidel, Ortho, QuidelOrtho (formerly Coronado Topco, Inc.), Orca Holdco, Inc., Laguna Merger Sub, Inc., and Orca Holdco 2, Inc.

Credit Agreement Credit agreement, dated May 27, 2022, by and among the Company, as borrower, Bank of America, N.A., as administrative agent and swing line lender, and the other lenders and

L/C issuers party thereto

EBITDA Earnings Before Interest, Taxes, Depreciation and Amortization

EMEA Europe, the Middle East and Africa

EPS (Loss) earnings per share

Exchange Act Securities Exchange Act of 1934, as amended

GAAP Generally Accepted Accounting Principles in the U.S.

Grifols Grifols Diagnostic Solutions, Inc.

IT Information technology

Joint Business Ongoing collaboration arrangement between Ortho and Grifols

JPAC Japan and Asia Pacific

OCI Other comprehensive (loss) income

Ortho Ortho Clinical Diagnostics Holdings plc

Quarterly Report Quarterly Report on Form 10-Q for the quarter ended March 31, 2024

Quidel Quidel Corporation

R&D Research and development

Revolving Credit Facility $800.0 million revolving credit facility under the Credit Agreement

RSU Restricted Stock Unit

RSV Respiratory Syncytial Virus

SEC Securities and Exchange Commission

Securities Act Securities Act of 1933, as amended

SOFR Secured Overnight Financing Rate

Stock Repurchase Program A stock repurchase program allowing the Company to repurchase up to $300.0 million of its common stock through August 17, 2024, which was authorized by our Board of Directors on August 17, 2022

Term Loan $2,750.0 million senior secured term loan facility under the Credit Agreement

United Kingdom

United States

USD United States Dollar

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

November 1, 2023 QUIDELORTHO CORPORATION

/s/ DOUGLAS C.

May 8, 2024 QUIDELORTHO CORPORATION

President and Chief Executive Officer

4 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information